Navigation Links
Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins
Date:9/3/2008

SYDNEY, Australia, Sept. 4 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it has enrolled the first subject into its second pivotal Phase 3 clinical trial evaluating Bronchitol in cystic fibrosis sufferers.

The Phase 3 trial is being conducted in 41 hospitals across North America, Argentina and Germany, and is the final clinical step before Pharmaxis seeks approval to market Bronchitol for cystic fibrosis in the United States.

Pharmaxis Chief Executive Officer Dr Alan Robertson said: "We are delighted to commence this trial following helpful discussions with the FDA and with assistance from the U.S. Cystic Fibrosis Foundation. This trial follows the recent closure to recruitment of the first Phase 3 trial involving 325 subjects. Bronchitol has been awarded fast-track status in the U.S., and orphan drug designation in both the U.S. and EU and we look forward to bringing Bronchitol to the international cystic fibrosis community as rapidly as we can."

This trial is being conducted under the Food and Drug Administration's Special Protocol Assessment (SPA) scheme. The SPA process ensures the clinical trial protocol is acceptable to the U.S. FDA when the results are submitted to support a marketing application for Bronchitol.

The Phase III clinical trial is designed to include a 26-week efficacy treatment period, followed by a 26-week safety period. The efficacy component of the trial is a randomized, double-blind investigation of Bronchitol twice daily in approximately 300 patients with cystic fibrosis. The trial is enrolling cystic fibrosis patients aged six years and older. Participants will be assessed for improvements in lung function, infectious episodes, antibiotic use, quality of life and a range of health economic measures. Further details concerning the trial are available at

SOURCE Pharmaxis Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent
2. Human Genome Sciences Completes Enrollment in Second Phase 3 LymphoStat-B(R) Trial
3. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
4. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
5. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
6. Genzyme and Isis Begin Second Phase 3 Trial Of Mipomersen
7. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
8. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
9. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results and Provide a Clinical Program Update on August 7, 2008
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014  Australian drug delivery company, Phosphagenics Limited (ASX: ... A$19.3 million via a placement of A$16.3 million to ... U.S., Asia and ... purchase plan (SPP) to be offered to existing shareholders. ... two tranches. "This capital raising positions us ...
(Date:7/11/2014)... 11, 2014 Research and Markets ( ... "Immunoprotein Diagnostic Testing Market - Forecasts to ... of 6% and is expected to be valued ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has been segmented according to immunoprotein types which ...
(Date:7/11/2014)... 2014 Neurelis, Inc. ("Neurelis") today announced an ... option held by Biotie to purchase Neurelis, clearing the ... (intranasal diazepam) for pediatric and adult epilepsy patients who ... year, Biotie has advanced the development program for NRL-1 ... clinical work required for NDA submission to the FDA.  ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3
... Aethlon Medical, Inc. (OTC Bulletin Board: ... to address infectious disease and cancer, announced today that ... Medicity Institute (Medicity) has approved a treatment program entitled: ... Infection in Combination with Standard of Care (SOC) Drug ...
... will help its guests reach their well-being goals by ... cold and flu season. Beginning Sept. 1, 2010, the ... Target Pharmacy and Target Clinic locations nationwide. Continuing its ... again offering the seasonal flu vaccine at the low ...
Cached Medicine Technology:Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 2Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 3Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 4Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 5Aethlon Medical Announces Approval of Hepatitis C Virus (HCV) Treatment Program 6Target to Serve as Prevention HQ this Flu Season 2
(Date:7/12/2014)... (PRWEB) July 12, 2014 The report, ... Alkyd Resins) Market by Application & Geography – Trends ... market with analysis and forecasting of market volume and ... of the derivatives separately. The market of phthalic anhydride ... in 2013 to $8,415.89 million by 2018, with a ...
(Date:7/12/2014)... The Security Analytics market is estimated to grow from ... at an expected CAGR of 9.7% for the period ... increasing number of security breaches, continued line of sophisticated ... organizations are enormous. Vendors in the security analytics market ... develop better and more secure systems. , There has ...
(Date:7/12/2014)... 2014 (HealthDay News) -- Burn injuries increase in the summer ... say burn experts. Among those most vulnerable to these seasonal ... vulnerable and often get burned by putting their hands on ... of the burn unit at Loyola University Medical Center in ... old adage of ,When you play with fire, you get ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 As DePuy ... forward in U.S. courts, Bernstein Liebhard LLP notes the ... ion levels to the failure of metal-on-metal hip replacements. ... of The Journal of Bone & Joint Surgery, looked ... Articular Surface Replacement prostheses at least twelve months earlier. ...
(Date:7/12/2014)... 12, 2014 Doylestown Hospital recently conducted ... of men’s health questions. Paddock tackles topics including ... why women live longer than men, and testosterone replacement ... Made Simple featured on Doylestown Hospital’s website, Dr. ... at any age. If you notice pain, bulging, or ...
Breaking Medicine News(10 mins):Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 2Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 3Health News:Phthalic Anhydride Market Projected to Reach $8.42 Billion by 2018 – Report by MarketsandMarkets 4Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Security Analytics Market Worth $1,215.2 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2
... because it comes with a computer's worst enemy: heat . ... and entire systems to become slower and less stable. A hot ... in fact, spell the end of a computer altogether. ... cool enough in the summertime. By paying attention to how much ...
... suggests why the commonly prescribed cholesterol-lowering drug ezetimibe (Zetia) ... at Wake Forest University School of Medicine, is reported ... will appear in the July 2 print issue. ... works by preventing cells in the intestine from absorbing ...
... scientist at annual conference of the European Society of ... can undergo chromosomal modifications. , Ms ... Hospital, Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel, ... that the results of preimplantation genetic screening (PGS) for ...
... filled the area in and around the football stadium in ... Puget Sound Race for the Cure . About 1,200 of ... others were running to honor family members who had died ... T-shirts and sporting the medallions awarded by the event organizers. ...
... Smile does seem to be working wonders for victims of ... of Cosmetic Dentistry, the nonprofit group is putting domestic violence ... ,To date, 500 applicants have been treated in ... or social worker must confirm that the injuries were caused ...
... the Toronto police busted a global Internet pedophile ring ... rescued more than 31 kids.700 suspects were rounded ... pornography network from a British-based website. The ring ... the Light of Our Lives" that featured images of ...
Cached Medicine News:Health News:Hot Tips for Keeping Your PC Cool in Summer 2Health News:Hot Tips for Keeping Your PC Cool in Summer 3Health News:Animal Research Uncovers Another Mechanism of Cholesterol Lowering Drug 2Health News:Preimplanted Genetic Screening Should Be Interpreted With Caution 2Health News:Annual Cancer Run Draws Huge Response in US 2Health News:US Dentists Help Victims of Domestic Violence Smile Again 2Health News:Thirty One Kids Rescued from a Pedophile Ring 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: